Early Diagnosis of High-Grade Serous Ovarian Cancer Feasible
By Elana Gotkine HealthDay Reporter
MONDAY, Dec. 11, 2023 -- Early diagnosis of high-grade serous ovarian cancer (HGSOC) seems feasible through analysis of genomic alterations in DNA from Papanicolaou (Pap) test smears, according to a study published online Dec. 6 in Science Translational Medicine.
Lara Paracchini, Ph.D., from Humanitas University in Milan, and colleagues examined a retrospective and multicentric cohort of 250 archival Pap test smears collected during routine gynecological screening. Samples were taken from 113 presymptomatic women who were subsequently diagnosed with HGSOC (pre-HGSOC) and from 77 healthy women at different time points (from one month to 13.5 years before diagnosis). Low-pass whole-genome sequencing of DNA derived from Pap test samples in terms of copy number profile abnormality (CPA) was used to detect genome instability.
The researchers found that the CPA values of DNA extracted from Pap samples were significantly higher from pre-HGSOC women versus healthy women. This assay could detect HGSOC presence up to nine years before diagnosis, consistent with the longitudinal analysis of clonal pathogenic TP53 mutations. Integration of the CPA score into the EVA (early ovarian cancer) test resulted in sensitivity, specificity, and accuracy of 75, 96, and 81 percent, respectively.
"We consider the data sufficiently convincing to warrant prospective clinical investigations aimed at verifying whether the longitudinal analysis of CPA in Pap test smears renders the prediction of HGSOC possible," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.